Basic Sildalis Information

• INN (International Nonproprietary Name): Sildalis does not have an official INN.
  Sildalis is a combination medication containing two active pharmaceutical ingredients: sildenafil citrate (INN: sildenafil) and tadalafil (INN: tadalafil).
• Brand Names Available In Australia: Sildalis is marketed as a non‑innovator, mostly internet‑sold combination drug.
  Packaging commonly shows red, oval tablets in blisters and is often labelled in English or Russian.
  It is primarily available through online pharmacies and unofficial distributors rather than registered local pharmacies or major Australian chains.
• ATC Code: Sildenafil is classified as G04BE03 and tadalafil as G04BE08.
  (G = Genito‑urinary system and sex hormones; G04 = Urologicals; G04BE = Drugs used in erectile dysfunction.)
• Forms & Dosages: Sildalis is sold as tablets.
  Typical strength listed is 100 mg sildenafil + 20 mg tadalafil.
  Typical packaging: blister packs of 6–20 tablets.
• Manufacturers In Australia: Sildalis is not produced by major originator companies such as Pfizer or Eli Lilly.
  Manufacturing is mostly by Indian generic companies or direct‑to‑web suppliers; it is not supplied through official registered pharma chains in Western markets.
• Registration Status In Australia: Sildalis is not registered with major national drug agencies as a combination product.
  There is no public record of a regulator‑approved sildenafil/tadalafil combination.
• OTC / Rx Classification: Where sildenafil or tadalafil are regulated, the product would be Prescription Only (Rx).
  However, Sildalis is often sold without prescription in online shops operating outside regulated supply chains.

Latest Research Highlights

Patients ask whether combining two PDE5 inhibitors gives better results and whether that’s been proven in trials.

Research from 2022 to mid‑2024 continues to show robust randomised controlled trial and observational evidence for single agents — sildenafil and tadalafil — in treating erectile dysfunction.

There are, however, no high‑quality, regulator‑approved clinical trials that formally evaluate fixed‑dose combination products such as Sildalis.

Pharmacokinetic and dedicated safety studies for a combined sildenafil+tadalafil tablet remain under‑studied and unreported in major agency registries.

Australian sources including TGA safety communications and pharmacoepidemiology reviews report class adverse events: headaches, flushing and visual effects (more typical with sildenafil) and myalgia or back pain (more typical with tadalafil).

Regulatory reviews and international systematic reviews flag serious risk when PDE5 inhibitors are used with nitrates or in people with unstable cardiac disease.

Clinician takeaway: evidence supports use of individual, TGA‑approved PDE5 inhibitors; claims that a combination pill like Sildalis confers superior, approved benefit are unsupported by formal regulatory trials.

Clinical Effectiveness In Australia

What works in Australian practice is usually a single, TGA‑approved PDE5 inhibitor prescribed and monitored by a GP or specialist.

Viagra (sildenafil) and Cialis (tadalafil) have TGA approval and a documented evidence base in Australia, with PBS listing for certain formulations and indications where applicable.

PBS data and TGA post‑market surveillance provide real‑world safety signals and outcome information for individual agents, but there is no TGA approval or PBS listing for a sildenafil+tadalafil combination tablet.

Sildalis is primarily internet‑sold and is not registered with major national drug agencies.

Effectiveness benchmarks in practice use validated scales such as the IIEF‑EF and feedback from primary care and telehealth services.

Comparison of single agents helps explain why some users seek combinations: sildenafil tends to have faster onset while tadalafil gives longer duration, but combined use lacks equivalent trial evidence and formal dosing studies for efficacy or safety.

Indications And Expanded Uses

People want clear guidance on when a product should be used and when it shouldn’t.

TGA‑approved indications in Australia cover erectile dysfunction for sildenafil and tadalafil, and sildenafil has additional licensed formulations for pulmonary arterial hypertension.

No agent is registered in Australia as a combined sildenafil+tadalafil product.

Internationally, Sildalis is marketed as a combination drug for ED and sold online outside official supply chains.

Off‑label discussions sometimes mention combining PDE5 inhibitors for treatment‑resistant cases or to try to match onset and duration, but such practices lack guideline support and carry increased risk of adverse effects.

1. Approved Indication: Erectile dysfunction — single agents only.
2. Off‑Label / Experimental: Combined dosing for enhanced potency/duration — no RCT support or regulatory approval.
3. Contraindicated Uses: Concurrent use with nitrates or riociguat, and in unstable cardiac disease.

Any expanded or off‑label use in Australia should be documented with informed consent, shared decision‑making and cardiology review where cardiovascular risk is present.

Composition And Brand Landscape

Many patients ask what’s actually in a Sildalis tablet and who makes it.

Sildalis is a fixed‑dose tablet combining sildenafil citrate and tadalafil.

Typical strength listed in online product descriptions is 100 mg sildenafil + 20 mg tadalafil, supplied in blister packs of 6–20 tablets.

Each active ingredient is a well recognised treatment for ED, but the combined product does not have an official INN and is not produced by the originator manufacturers such as Pfizer or Eli Lilly.

Manufacture is mostly by Indian generic companies or direct‑to‑web suppliers and the product is primarily sold via online pharmacies rather than major Australian retail pharmacy chains.

Consumers should be aware of risks associated with non‑registered manufacturers and consider safer, TGA‑approved generics such as sildenafil Pfizer or authorised tadalafil brands available via Australian pharmacies.

Contraindications And Special Precautions

Patients commonly worry about heart medicine interactions and whether the pill is safe for older family members.

Absolute contraindications that apply to any PDE5 inhibitor also apply to Sildalis per product information: known allergy to sildenafil or tadalafil, concurrent nitrates, and use with riociguat are absolute contraindications.

Severe cardiovascular disease that makes sexual activity inadvisable is also an absolute contraindication.

Relative cautions include significant hepatic or renal impairment, recent stroke or myocardial infarction, unstable angina and rare eye disorders such as retinitis pigmentosa.

Special populations in Australian practice need attention: older adults should start at lower doses and be monitored for hypotension.

People in rural, remote and Indigenous communities may have higher undiagnosed cardiovascular risk; clinicians should screen carefully before any off‑label supply.

• Counselling Checklist: check nitrates, review cardiac history, assess liver/kidney function, advise on alcohol and driving, warn about priapism and chest pain.
• Red Flags: chest pain, sudden syncope, prolonged erection (>4 hours) — seek urgent care.

When prescribing via telehealth, document baseline blood pressure and ECG where appropriate and refer to local cardiology for uncertain risk profiles.

Dosage Guidelines

One of the most frequent queries is what dose to start and how to adjust it safely.

Marketed Sildalis dose descriptions list one tablet containing 100 mg sildenafil and 20 mg tadalafil taken about 30–60 minutes before sexual activity, not more than once per 24 hours.

Australian prescribing practice for single agents usually starts at lower doses — for example sildenafil 50 mg or tadalafil 10 mg — and titrates according to efficacy and tolerability.

Fixed‑high dosing like a 100/20 mg combination is not standard practice in Australia and lacks formal dosing studies or regulatory guidance.

Clinicians should document reasons for any off‑label dosing, counsel about the delayed but longer action of tadalafil versus the faster onset of sildenafil, and advise medical review for persistent symptoms or side effects.

Interactions Overview

People often ask whether their current medicines are safe to take with ED pills.

The critical contraindication is co‑administration with nitrates, which can cause life‑threatening hypotension.

Use with riociguat is also strictly contraindicated.

Potent CYP3A4 inhibitors such as ketoconazole or ritonavir increase PDE5 inhibitor exposure and require dose modification for individual agents; combination product effects are unstudied.

Alpha‑blockers can cause symptomatic hypotension when used together with PDE5 inhibitors, so careful timing and dose adjustments are necessary.

In Australian practice, pharmacists should screen PBS histories and My Health Record to avoid dangerous co‑prescribing, particularly with rapid telehealth supply models that bypass usual checks.

Cultural Perceptions And Patient Habits In Australia

Many Australians prefer a discreet route to treatment, which changes how products are sourced and used.

Attitudes combine pragmatism, price sensitivity and trust in pharmacists.

Men often seek telehealth or online purchase to reduce stigma, but many still prefer face‑to‑face pharmacy advice from Chemist Warehouse, Priceline or TerryWhite Chemmart.

Rural and remote Australians face access barriers such as fewer clinics and longer travel, which increases the appeal of online purchases and potential uptake of unregulated products like Sildalis.

Indigenous men may require culturally safe, community‑based approaches and have a higher cardiovascular risk profile that needs careful screening before prescribing PDE5 inhibitors.

• Access Patterns: urban clinic, telehealth, online marketplaces.
• Trust Drivers: PBS subsidies, pharmacist counselling, local clinic relationships.
• Cultural Considerations: privacy concerns, stigma, need for culturally respectful care.

Health messaging should focus on safety, TGA regulation and encourage prescriptions through accredited telehealth services linked to local pharmacists.

Availability And Pricing Patterns

Where to buy and how much it costs are practical concerns for many people.

Sildalis is primarily available through online pharmacies and unofficial distributors and is not registered with major regulatory agencies nor listed on the PBS.

Authorised sildenafil and tadalafil products are dispensed via major Australian chains with variable private prices, and certain generics or formulations may be PBS‑listed.

Typical online vendors often undercut retail prices, but that comes with greater regulatory and counterfeit risk.

In our online pharmacy, sildalis is available without a prescription, with discreet delivery to Australia in 5–14 days.

Consumers should beware non‑TGA‑registered products and choose telehealth‑linked e‑prescriptions that route to registered pharmacies for safe, documented supply.

Comparable Medicines And Preferences

Patients ask whether a combination is better than single‑agent therapy.

Alternatives available in Australia include sildenafil (Viagra and generics), tadalafil (Cialis and generics) and other PDE5 inhibitors such as vardenafil.

Each option has trade‑offs: sildenafil has faster onset and shorter duration while tadalafil can last up to 36 hours and tends to cause more myalgia.

Sildalis markets an “enhanced potency” combination, but there is no regulatorily approved evidence showing improved outcomes over monotherapy.

• Pros Of Single Agents: established evidence base, clear dosing, known safety profile, PBS or generic options.
• Cons Of Combination: unstudied pharmacokinetics, undefined dosing adjustments, potential for increased adverse events.

For many patients, optimising a single agent, adjusting timing and dose, and addressing lifestyle factors such as smoking cessation and treating comorbidities gives the best outcomes.

If first‑line agents fail, clinicians should consider referral to urology or sexual health services rather than unsupervised combination therapy.

Frequently Asked Questions

Q: Is Sildalis legal and safe in Australia?

A: Sildalis is not TGA‑registered as a combination product and its safety profile for combined dosing is unstudied.

Q: Can I take Sildalis with my heart medicine?

A: Never take Sildalis with nitrates.

All cardiac medicines should be reviewed by a GP or pharmacist and checked against PBS or My Health Record for interactions.

Q: Is Sildalis better than Viagra or Cialis?

A: No high‑quality evidence supports superiority of a fixed sildenafil+tadalafil product; single agents have established evidence and should be preferred first.

Q: How can I buy safely?

A: Use registered Australian pharmacies, telehealth prescriptions linked to local chemists and avoid unverified online sellers to reduce counterfeit and safety risks.

Guidelines For Proper Use And Pharmacist Counselling

Pharmacist counselling is often the moment a patient decides whether a product is safe and appropriate.

Verify prescription legitimacy and perform a medication reconciliation using My Health Record or PBS medication history where available.

Screen for nitrates, riociguat and cardiovascular risk before dispensing any PDE5 inhibitor.

Advise expected onset and duration: sildenafil typically 30–60 minutes; tadalafil has a longer duration of effect.

Warn about common side effects and when to seek emergency care: chest pain, syncope or erections lasting more than four hours.

1. Medication Reconciliation: verify all current medicines and check for nitrates and CYP3A4 inhibitors.
2. Contraindication Check: ensure no riociguat or recent major cardiac events.
3. Dosing And Timing: explain onset/duration and advise lower starting doses for older adults.
4. Adverse Effect Management: hydration, avoid heavy alcohol, report visual changes, manage priapism urgently.
5. Storage And Sourcing: store below 30°C, keep out of reach of children, avoid unverified online sources.

For rural patients, arrange local pharmacy pickup or community health centre follow‑up and discuss PBS or generic alternatives where cost is a concern.

Document counselling and any informed consent if an off‑label supply is considered, and refer to cardiology or urology when indicated.

Delivery Across Australia